Vantage logo

The Cymabay recovery continues

Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.

Vantage logo

The dream is over for Intercept

The company blasts the US regulator as weeks of uncertainty for its lead drug in Nash end in a complete response letter.